碳青霉烯耐药肺炎克雷伯菌头孢他啶–阿维巴坦耐药机制研究进展综述
A Review of Research Progress on the Mechanisms of Resistance to Ceftazidime-Avibactam in Carbapenem-Resistant Klebsiella pneumoniae
摘要: 头孢他啶–阿维巴坦被称为碳青霉烯耐药肺炎克雷伯菌(Carbapenem-Resistant Klebsiella pneumoniae, CRKP)的最后一道防线，随着临床上的不合理使用，越来越多的耐药机制被报道，最常见的有β-内酰胺酶关键位点氨基酸突变、blaKPC基因过表达及膜孔蛋白突变导致细胞膜通透性障碍。本文详细地总结了头孢他啶–阿维巴坦的药理特点、耐药现状，以及耐药机制，旨在给头孢他啶–阿维巴坦耐药防控及多重耐药肺炎克雷伯杆菌的临床治疗提供科学思路。
Abstract: Ceftazidime-avibactam is regarded as the last line of defense against Carbapenem-resistant Klebsiella pneumoniae (CRKP). However, with its irrational clinical use, an increasing number of resistance mechanisms have been reported. The most common mechanisms include amino acid mutations at critical sites of β-lactamases, overexpression of the blaKPC gene, and mutations in porin proteins that lead to impaired cell membrane permeability. This article provides a detailed summary of the pharmacological characteristics, current resistance status, and resistance mechanisms of ceftazidime-avibactam, aiming to offer scientific insights for the prevention and control of ceftazidime-avibactam resistance and the clinical treatment of multidrug-resistant Klebsiella pneumoniae.
文章引用：陈新维, 俞云松. 碳青霉烯耐药肺炎克雷伯菌头孢他啶–阿维巴坦耐药机制研究进展综述[J]. 临床医学进展, 2025, 15(8): 1827-1835. https://doi.org/10.12677/acm.2025.1582432

参考文献

[1] Dong, N., Yang, X., Chan, E.W., Zhang, R. and Chen, S. (2022) Klebsiella Species: Taxonomy, Hypervirulence and Multidrug Resistance. eBioMedicine, 79, Article ID: 103998. [Google Scholar] [CrossRef] [PubMed]
[2] World Health Organization (2024) WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance.
https://www.who.int/publications/i/item/9789240093461
[3] Zhanel, G.G., Lawson, C.D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P.R.S., et al. (2013) Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination. Drugs, 73, 159-177. [Google Scholar] [CrossRef] [PubMed]
[4] Nahar, L., Hagiya, H., Gotoh, K., Asaduzzaman, M. and Otsuka, F. (2024) New Delhi Metallo-Beta-Lactamase Inhibitors: A Systematic Scoping Review. Journal of Clinical Medicine, 13, Article 4199. [Google Scholar] [CrossRef] [PubMed]
[5] Zakhour, J., El Ayoubi, L.W. and Kanj, S.S. (2024) Metallo-Beta-Lactamases: Mechanisms, Treatment Challenges, and Future Prospects. Expert Review of Anti-Infective Therapy, 22, 189-201. [Google Scholar] [CrossRef] [PubMed]
[6] Khalid, S., Migliaccio, A., Zarrilli, R. and Khan, A.U. (2023) Efficacy of Novel Combinations of Antibiotics against Multidrug-Resistant—New Delhi Metallo-Beta-Lactamase-Producing Strains of Enterobacterales. Antibiotics, 12, Article 1134. [Google Scholar] [CrossRef] [PubMed]
[7] 喻华, 徐雪松, 李敏, 等. 肠杆菌目细菌碳青霉烯酶的实验室检测和临床报告规范专家共识(第二版) [J]. 中国感染与化疗杂志, 2022, 22(4): 463-474.
[8] Yang, Y., Guo, Y., Yin, D., Zheng, Y., Wu, S., Zhu, D., et al. (2020) In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018. Antimicrobial Agents and Chemotherapy, 65, 1-8. [Google Scholar] [CrossRef] [PubMed]
[9] Chen, Y., Huang, H., Peng, J., Weng, L. and Du, B. (2022) Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: A Systematic Review and Meta-Analysis. Microbiology Spectrum, 10, e02603-21. [Google Scholar] [CrossRef] [PubMed]
[10] Davido, B., Crémieux, A., Vaugier, I., Gatin, L., Noussair, L., Massias, L., et al. (2023) Efficacy of Ceftazidime-Avibactam in Various Combinations for the Treatment of Experimental Osteomyelitis Due to Klebsiella pneumoniae Carbapenemase (KPC)-Producing Klebsiella pneumoniae. International Journal of Antimicrobial Agents, 61, Article ID: 106702. [Google Scholar] [CrossRef] [PubMed]
[11] Almyroudi, M.P., Chang, A., Andrianopoulos, I., Papathanakos, G., Mehta, R., Paramythiotou, E., et al. (2024) Novel Antibiotics for Gram-Negative Nosocomial Pneumonia. Antibiotics, 13, Article 629. [Google Scholar] [CrossRef] [PubMed]
[12] de Jonge, B.L.M., Karlowsky, J.A., Kazmierczak, K.M., Biedenbach, D.J., Sahm, D.F. and Nichols, W.W. (2016) In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrobial Agents and Chemotherapy, 60, 3163-3169. [Google Scholar] [CrossRef] [PubMed]
[13] Spiliopoulou, I., Kazmierczak, K. and Stone, G.G. (2019) In Vitro Activity of Ceftazidime/Avibactam against Isolates of Carbapenem-Non-Susceptible Enterobacteriaceae Collected during the INFORM Global Surveillance Programme (2015-17). Journal of Antimicrobial Chemotherapy, 75, 384-391. [Google Scholar] [CrossRef] [PubMed]
[14] Stone, G.G., Seifert, H. and Nord, C.E. (2020) In Vitro Activity of Ceftazidime-Avibactam against Gram-Negative Isolates Collected in 18 European Countries, 2015-2017. International Journal of Antimicrobial Agents, 56, Article ID: 106045. [Google Scholar] [CrossRef] [PubMed]
[15] Karlowsky, J.A., Kazmierczak, K.M., de Figueiredo Valente, M.L.N., Luengas, E.L., Baudrit, M., Quintana, A., et al. (2021) In Vitro Activity of Ceftazidime-Avibactam against Enterobacterales and Pseudomonas Aeruginosa Isolates Collected in Latin America as Part of the ATLAS Global Surveillance Program, 2017-2019. The Brazilian Journal of Infectious Diseases, 25, Article ID: 101647. [Google Scholar] [CrossRef] [PubMed]
[16] Bae, I. and Stone, G.G. (2022) In Vitro Activity of Ceftazidime-Avibactam and Comparators against Bacterial Isolates Collected in South Korea as Part of the ATLAS Global Surveillance Program (2016-2018). Diagnostic Microbiology and Infectious Disease, 102, Article ID: 115553. [Google Scholar] [CrossRef] [PubMed]
[17] Ko, W. and Stone, G.G. (2020) In Vitro Activity of Ceftazidime-Avibactam and Comparators against Gram-Negative Bacterial Isolates Collected in the Asia-Pacific Region as Part of the INFORM Program (2015-2017). Annals of Clinical Microbiology and Antimicrobials, 19, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[18] Karlowsky, J.A., Kazmierczak, K.M., Bouchillon, S.K., de Jonge, B.L.M., Stone, G.G. and Sahm, D.F. (2018) In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas Aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrobial Agents and Chemotherapy, 62, e02569-17. [Google Scholar] [CrossRef] [PubMed]
[19] 郭燕, 胡付品, 朱德妹, 等. 2023年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2024, 24(6): 627-637.
[20] Ding, L., Shen, S., Chen, J., Tian, Z., Shi, Q., Han, R., et al. (2023) Klebsiella pneumoniae Carbapenemase Variants: The New Threat to Global Public Health. Clinical Microbiology Reviews, 36, 1-26. [Google Scholar] [CrossRef] [PubMed]
[21] Shi, Q., Shen, S., Tang, C., Ding, L., Guo, Y., Yang, Y., et al. (2024) Molecular Mechanisms Responsible Kpc-135-Mediated Resistance to Ceftazidime-Avibactam in ST11-K47 Hypervirulent Klebsiella pneumoniae. Emerging Microbes & Infections, 13, Article ID: 2361007. [Google Scholar] [CrossRef] [PubMed]
[22] Tang, C., Shen, S., Yang, W., Shi, Q., Ding, L., Han, R., et al. (2024) Dynamic Evolution of Ceftazidime-Avibactam Resistance from a Single Patient through the Incx3_ndm-5 Plasmid Transfer and blaKPC Mutation. International Journal of Antimicrobial Agents, 64, Article ID: 107228. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, P., Shi, Q., Hu, H., Hong, B., Wu, X., Du, X., et al. (2020) Emergence of Ceftazidime/Avibactam Resistance in Carbapenem-Resistant Klebsiella pneumoniae in China. Clinical Microbiology and Infection, 26, 124.E1-124.E4. [Google Scholar] [CrossRef] [PubMed]
[24] Tang, C., Shen, S., Yang, W., Shi, Q., Ding, L., Han, R., et al. (2024) Complex Evolutionary Trajectories in Vivo of Two Novel KPC Variants Conferring Ceftazidime-Avibactam Resistance. International Journal of Antimicrobial Agents, 64, Article 107265. [Google Scholar] [CrossRef] [PubMed]
[25] Yang, W., Xu, H., Zhao, Y., Chen, W., Ma, X. and Hu, F. (2025) Identification of blaKPC-90 in Klebsiella pneumoniae Associated with Ceftazidime-Avibactam Resistance and the Translocation & Truncation of Resistant Genes Mediated by Is26. International Journal of Antimicrobial Agents, 65, Article ID: 107388. [Google Scholar] [CrossRef] [PubMed]
[26] Zhou, J., Yan, G., Tang, C., Liu, J., Fu, P., Ding, L., et al. (2024) Emergence of Ceftazidime-Avibactam Resistance in blaKPC-33-Harbouring ST11 Klebsiella pneumoniae in a Paediatric Patient. International Journal of Antimicrobial Agents, 63, Article ID: 107163. [Google Scholar] [CrossRef] [PubMed]
[27] Abboud, M.I., Damblon, C., Brem, J., Smargiasso, N., Mercuri, P., Gilbert, B., et al. (2016) Interaction of Avibactam with Class B Metallo-β-lactamases. Antimicrobial Agents and Chemotherapy, 60, 5655-5662. [Google Scholar] [CrossRef] [PubMed]
[28] Li, S., Feng, X., Li, M. and Shen, Z. (2023) In Vivo Adaptive Antimicrobial Resistance in Klebsiella pneumoniae during Antibiotic Therapy. Frontiers in Microbiology, 14, Article ID: 1159912. [Google Scholar] [CrossRef] [PubMed]
[29] Barnes, M.D., Winkler, M.L., Taracila, M.A., Page, M.G., Desarbre, E., Kreiswirth, B.N., et al. (2017) Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering. mBio, 8, e00528-17. [Google Scholar] [CrossRef] [PubMed]
[30] Winkler, M.L., Papp-Wallace, K.M. and Bonomo, R.A. (2015) Activity of Ceftazidime/Avibactam against Isogenic Strains of Escherichia coli Containing KPC and SHV β-Lactamases with Single Amino Acid Substitutions in the Ω-Loop. Journal of Antimicrobial Chemotherapy, 70, 2279-2286. [Google Scholar] [CrossRef] [PubMed]
[31] Alsenani, T.A., Viviani, S.L., Kumar, V., Taracila, M.A., Bethel, C.R., Barnes, M.D., et al. (2022) Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 66, e0241421. [Google Scholar] [CrossRef] [PubMed]
[32] Garsevanyan, S. and Barlow, M. (2023) The Klebsiella pneumoniae Carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam. Antibiotics, 13, Article 40. [Google Scholar] [CrossRef] [PubMed]
[33] Parwana, D., Gu, J., Chen, S., Bethel, C.R., Marshall, E., Hujer, A.M., et al. (2024) The Structural Role of N170 in Substrate-Assisted Deacylation in KPC-2 β-Lactamase. Angewandte Chemie International Edition, 63, e202317315. [Google Scholar] [CrossRef] [PubMed]
[34] Shields, R.K., Chen, L., Cheng, S., Chavda, K.D., Press, E.G., Snyder, A., et al. (2017) Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrobial Agents and Chemotherapy, 61, e02097-16. [Google Scholar] [CrossRef] [PubMed]
[35] Shields, R.K., Nguyen, M.H., Press, E.G., Chen, L., Kreiswirth, B.N. and Clancy, C.J. (2017) Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K Pneumoniae: A Case Report and Review of Literature. Open Forum Infectious Diseases, 4, ofx101. [Google Scholar] [CrossRef] [PubMed]
[36] Oueslati, S., Iorga, B.I., Tlili, L., Exilie, C., Zavala, A., Dortet, L., et al. (2019) Unravelling Ceftazidime/Avibactam Resistance of KPC-28, a KPC-2 Variant Lacking Carbapenemase Activity. Journal of Antimicrobial Chemotherapy, 74, 2239-2246. [Google Scholar] [CrossRef] [PubMed]
[37] Hemarajata, P. and Humphries, R.M. (2019) Ceftazidime/Avibactam Resistance Associated with L169P Mutation in the Omega Loop of KPC-2. Journal of Antimicrobial Chemotherapy, 74, 1241-1243. [Google Scholar] [CrossRef] [PubMed]
[38] Shi, Q., Yin, D., Han, R., Guo, Y., Zheng, Y., Wu, S., et al. (2020) Emergence and Recovery of Ceftazidime-Avibactam Resistance In blaKPC-33-Harboring Klebsiella pneumoniae Sequence Type 11 Isolates in China. Clinical Infectious Diseases, 71, S436-S439. [Google Scholar] [CrossRef] [PubMed]
[39] Gaibani, P., Ambretti, S., Campoli, C., Viale, P. and Re, M.C. (2020) Genomic Characterization of a Klebsiella pneumoniae ST1519 Resistant to Ceftazidime/Avibactam Carrying a Novel KPC Variant (kpc-36). International Journal of Antimicrobial Agents, 55, Article ID: 105816. [Google Scholar] [CrossRef] [PubMed]
[40] Sun, L., Chen, W., Li, H., Li, L., Zou, X., Zhao, J., et al. (2020) Phenotypic and Genotypic Analysis of KPC-51 and KPC-52, Two Novel KPC-2 Variants Conferring Resistance to Ceftazidime/Avibactam in the KPC-Producing Klebsiella pneumoniae ST11 Clone Background. Journal of Antimicrobial Chemotherapy, 75, 3072-3074. [Google Scholar] [CrossRef] [PubMed]
[41] Li, X., Ke, H., Wu, W., Tu, Y., Zhou, H. and Yu, Y. (2021) Molecular Mechanisms Driving the in Vivo Development of Kpc-71-Mediated Resistance to Ceftazidime-Avibactam during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. mSphere, 6, e0085921. [Google Scholar] [CrossRef] [PubMed]
[42] Shen, S., Tang, C., Ding, L., Han, R., Yin, D., Yang, W., et al. (2022) Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam. mSphere, 7, e0048722. [Google Scholar] [CrossRef] [PubMed]
[43] Galani, I., Antoniadou, A., Karaiskos, I., Kontopoulou, K., Giamarellou, H. and Souli, M. (2019) Genomic Characterization of a KPC-23-Producing Klebsiella pneumoniae ST258 Clinical Isolate Resistant to Ceftazidime-Avibactam. Clinical Microbiology and Infection, 25, 763.E5-763.E8. [Google Scholar] [CrossRef] [PubMed]
[44] Antonelli, A., Giani, T., Di Pilato, V., Riccobono, E., Perriello, G., Mencacci, A., et al. (2019) KPC-31 Expressed in a Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae Is Associated with Relevant Detection Issues. Journal of Antimicrobial Chemotherapy, 74, 2464-2466. [Google Scholar] [CrossRef] [PubMed]
[45] Carattoli, A., Arcari, G., Bibbolino, G., Sacco, F., Tomolillo, D., Di Lella, F.M., et al. (2021) Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates. Antimicrobial Agents and Chemotherapy, 65, e0057421. [Google Scholar] [CrossRef] [PubMed]
[46] Mueller, L., Masseron, A., Prod’Hom, G., Galperine, T., Greub, G., Poirel, L., et al. (2019) Phenotypic, Biochemical, and Genetic Analysis of KPC-41, a KPC-3 Variant Conferring Resistance to Ceftazidime-Avibactam and Exhibiting Reduced Carbapenemase Activity. Antimicrobial Agents and Chemotherapy, 63, e01111-19. [Google Scholar] [CrossRef] [PubMed]
[47] Poirel, L., Vuillemin, X., Juhas, M., Masseron, A., Bechtel-Grosch, U., Tiziani, S., et al. (2020) KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity. Antimicrobial Agents and Chemotherapy, 64, e00321-20. [Google Scholar] [CrossRef] [PubMed]
[48] Guzmán-Puche, J., Pérez-Nadales, E., Pérez-Vázquez, M., Causse, M., Gracia-Ahufinger, I., Mendez-Natera, A., et al. (2022) In Vivo Selection of KPC-94 and KPC-95 in Klebsiella pneumoniae Isolates from Patients Treated with Ceftazidime/Avibactam. International Journal of Antimicrobial Agents, 59, Article ID: 106524. [Google Scholar] [CrossRef] [PubMed]
[49] Nicola, F., Cejas, D., González-Espinosa, F., Relloso, S., Herrera, F., Bonvehí, P., et al. (2022) Outbreak of Klebsiella pneumoniae ST11 Resistant to Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina. Microbiology Spectrum, 10, e0373322. [Google Scholar] [CrossRef] [PubMed]
[50] Gaibani, P., Amadesi, S., Lazzarotto, T. and Ambretti, S. (2022) Genome Characterization of a Klebsiella pneumoniae Co-Producing OXA-181 and KPC-121 Resistant to Ceftazidime/Avibactam, Meropenem/Vaborbactam, Imipenem/Relebactam and Cefiderocol Isolated from a Critically Ill Patient. Journal of Global Antimicrobial Resistance, 30, 262-264. [Google Scholar] [CrossRef] [PubMed]
[51] Castanheira, M., Simner, P.J. and Bradford, P.A. (2021) Extended-Spectrum β-Lactamases: An Update on Their Characteristics, Epidemiology and Detection. JAC-Antimicrobial Resistance, 3, dlab092. [Google Scholar] [CrossRef] [PubMed]
[52] Both, A., Büttner, H., Huang, J., Perbandt, M., Belmar Campos, C., Christner, M., et al. (2017) Emergence of Ceftazidime/Avibactam Non-Susceptibility in an MDR Klebsiella pneumoniae Isolate. Journal of Antimicrobial Chemotherapy, 72, 2483-2488. [Google Scholar] [CrossRef] [PubMed]
[53] Livermore, D.M., Mushtaq, S., Doumith, M., Jamrozy, D., Nichols, W.W. and Woodford, N. (2018) Selection of Mutants with Resistance or Diminished Susceptibility to Ceftazidime/Avibactam from ESBL-and AmpC-Producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 73, 3336-3345. [Google Scholar] [CrossRef] [PubMed]
[54] Zhao, J., Pu, D., Li, Z., Zhang, Y., Liu, X., Zhuo, X., et al. (2024) Loss and Gain of Ceftazidime-Avibactam Susceptibility in a Non-Carbapenemase-Producing K1-ST23 Hypervirulent klebsiella pneumoniae. Virulence, 15, Article ID: 2348251. [Google Scholar] [CrossRef] [PubMed]
[55] Fröhlich, C., Sørum, V., Thomassen, A.M., Johnsen, P.J., Leiros, H.S. and Samuelsen, Ø. (2019) OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs. mSphere, 4, e00024-19. [Google Scholar] [CrossRef] [PubMed]
[56] Yoshizumi, A., Ishii, Y., Aoki, K., Testa, R., Nichols, W.W. and Tateda, K. (2015) In Vitro Susceptibility of Characterized β-Lactamase-Producing Gram-Negative Bacteria Isolated in Japan to Ceftazidime-, Ceftaroline-, and Aztreonam-Avibactam Combinations. Journal of Infection and Chemotherapy, 21, 148-151. [Google Scholar] [CrossRef] [PubMed]
[57] Shields, R.K., Clancy, C.J., Hao, B., Chen, L., Press, E.G., Iovine, N.M., et al. (2015) Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on the in Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. Pneumoniae. Antimicrobial Agents and Chemotherapy, 59, 5793-5797. [Google Scholar] [CrossRef] [PubMed]
[58] Humphries, R.M., Yang, S., Hemarajata, P., Ward, K.W., Hindler, J.A., Miller, S.A., et al. (2015) First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate. Antimicrobial Agents and Chemotherapy, 59, 6605-6607. [Google Scholar] [CrossRef] [PubMed]
[59] Humphries, R.M. and Hemarajata, P. (2017) Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3. Antimicrobial Agents and Chemotherapy, 61, e00537-17. [Google Scholar] [CrossRef] [PubMed]
[60] Castanheira, M., Doyle, T.B., Hubler, C., Sader, H.S. and Mendes, R.E. (2020) Ceftazidime-Avibactam Activity against a Challenge Set of Carbapenem-Resistant Enterobacterales: Ompk36 L3 Alterations and β-Lactamases with Ceftazidime Hydrolytic Activity Lead to Elevated MIC Values. International Journal of Antimicrobial Agents, 56, Article ID: 106011. [Google Scholar] [CrossRef] [PubMed]
[61] Shi, Q., Han, R., Guo, Y., Yang, Y., Wu, S., Ding, L., et al. (2022) Multiple Novel Ceftazidime-Avibactam-Resistant Variants of blaKPC-2-Positive Klebsiella pneumoniae in Two Patients. Microbiology Spectrum, 10, e0171421. [Google Scholar] [CrossRef] [PubMed]
[62] Gong, G., Chen, Q., Luo, J., Wang, Y., Li, X., Zhang, F., et al. (2023) Characteristics of a Ceftadine/Avibatam Resistance Kpc-33-Producing Klebsiella pneumoniae Strain with Capsular Serotype K19 Belonging to St15. Journal of Global Antimicrobial Resistance, 35, 159-162. [Google Scholar] [CrossRef] [PubMed]
[63] Shen, Z., Ding, B., Ye, M., Wang, P., Bi, Y., Wu, S., et al. (2017) High Ceftazidime Hydrolysis Activity and Porin Ompk35 Deficiency Contribute to the Decreased Susceptibility to Ceftazidime/Avibactam in KPC-Producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 72, 1930-1936. [Google Scholar] [CrossRef] [PubMed]
[64] Sun, L., Li, H., Wang, Q., Liu, Y. and Cao, B. (2021) Increased Gene Expression and Copy Number of Mutated blaKPC Lead to High-Level Ceftazidime/Avibactam Resistance in Klebsiella pneumoniae. BMC Microbiology, 21, Article No. 230. [Google Scholar] [CrossRef] [PubMed]

为你推荐